Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
10
×
biotech
national blog main
national top stories
boston blog main
boston top stories
san francisco blog main
startups
clinical trials
deals
san diego blog main
san diego top stories
boston
fda
national
new york blog main
new york top stories
san diego
san francisco top stories
acute myeloid leukemia
cancer drugs
europe blog main
exome
genomics
investing
ipo
life science
precision medicine
third rock ventures
vc
480 biomedical
acetylon pharmaceuticals
adverum biotechnologies
ally bridge group
alx oncology
ambit biosciences
ambys medicines
arsenal medical
athena countouriotis
autoimmune diseases
What
biotech
10
×
new
10
×
ipo
medicines
raised
research
therapeutics
drug
life
million
cancer
companies
company
developing
diseases
genomics
lead
medical
medicine
podcast
precision
raises
san
sciences
startup
aiming
aims
ambys
analysis
approach
arrival
athena
attract
attracted
attractive
based
big
bio
biotechnology
black
Language
unset
Current search:
new
×
" life sciences "
×
biotech
×
@tech.eu
2 years ago
Why biotech investors are attracted to Lithuania
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Explore San Diego’s Precision Medicine and Genomics Sector in Xconomy’s New Podcast and Special Report
@xconomy.com
4 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Podcast: How San Diego is Building a Biotech Ecosystem – Genomics & Precision Medicine Experts Weigh in
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?